Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database

被引：1
|
作者：
Jiang, Cindy Y.
Hwang, Hyunsoo
Jindal, Tanya
Qiao, Wei
Epstein, Ilana
Nguyen, Charles B.
Gupta, Shilpa
Shah, Sumit
Bilen, Mehmet Asim
Milowsky, Matthew I.
Hoimes, Christopher J.
Kilari, Deepak
Zakharia, Yousef
Emamekhoo, Hamid
Grivas, Petros
Bellmunt, Joaquim
Alva, Ajjai Shivaram
Koshkin, Vadim S.
Campbell, Matthew T.
Alhalabi, Omar
机构：
[1] Univ Texas MD Anderson Hematol Oncol Fellowship, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Michigan Med, Ann Arbor, MI USA
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Stanford Canc Ctr, Stanford, CA USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[10] Duke Univ, Duke Canc Inst, Durham, NC USA
[11] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[12] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
[13] Univ Wisconsin, Madison, WI USA
[14] Univ Washington, Div Hematol & Oncol, Seattle, WA 98195 USA
[15] Fred Hutchinson Canc Ctr, Seattle, WA USA
[16] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
[17] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[18] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 32 条
  • [1] Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Khaki, Ali Raza
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Shah, Sumit
    Zakharia, Yousef
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Emamekhoo, Hamid
    Davis, Nancy B.
    Grivas, Petros
    Gupta, Shilpa
    Hoimes, Christopher J.
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [2] Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
    Jindal, Tanya
    Zhang, Li
    Jiang, Cindy
    Kilari, Deepak
    Alhalabi, Omar
    Nizam, Amanda
    Basu, Arnab
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Milowsky, Matthew I.
    Shah, Sumit
    Hoimes, Christopher J.
    Davis, Nancy B.
    Gupta, Shilpa
    Emamekhoo, Hamid
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
    Loriot, Yohann
    Matsubara, Nobuaki
    Park, Se Hoon
    Huddart, Robert A.
    Burgess, Earle F.
    Houede, Nadine
    Banek, Severine
    Laguerre, Brigitte
    Guadalupi, Valentina
    Ku, Ja Hyeon
    Triantos, Spyros
    Akapame, Sydney
    Deprince, Kris
    Mukhopadhyay, Sutapa
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [4] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
    Matsubara, Nobuaki
    Park, Se Hoon
    Huddart, Robert A.
    Burgess, Earle F.
    Houede, Nadine
    Banek, Severine
    Laguerre, Brigitte
    Guadalupi, Valentina
    Ku, Ja Hyeon
    Triantos, Spyros
    Akapame, Sydney
    Deprince, Kris
    Mukhopadhyay, Sutapa
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4619 - LBA4619
  • [5] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
    Banek, S.
    Loriot, Y.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Houede, N.
    Laguerre, B.
    Guadalupi, V
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 94 - 94
  • [6] Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
    Siefker-Radtke, A. O.
    Loriot, Y.
    Siena, S.
    Beato, C.
    Climent Duran, M. A.
    Varlamov, S.
    Duran, I.
    Tagawa, S. T.
    Geoffrois, L.
    Mellado, B.
    Semenov, A.
    Delva, R.
    Lykov, A. P.
    Dirix, L. Y.
    Akapame, S.
    O'Hagan, A.
    Tammaro, M.
    Mosher, S.
    Kang, T. W.
    Moreno, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S584 - S585
  • [7] Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.
    Jiang, Cindy Y.
    Jindal, Tanya
    Epstein, Ilana B.
    Nguyen, Charles B.
    Nizam, Amanda
    Bakaloudi, Dimitra Rafailia
    Taylor, Amy K.
    Milowsky, Matthew I.
    Shah, Sumit
    Hoimes, Christopher J.
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Emamekhoo, Hamid
    Grivas, Petros
    Gupta, Shilpa
    Bellmunt, Joaquim
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Alhalabi, Omar
    Campbell, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
    Siefker-Radtke, A.
    Zhong, B.
    Qi, K.
    Shalaby, W.
    De Porre, P.
    O'Hagan, A.
    Mahadevia, P.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
    Matsubara, Nobuaki
    Miura, Yuji
    Nishiyama, Hiroyuki
    Taoka, Rikiya
    Kojima, Takahiro
    Shimizu, Nobuaki
    Hwang, Jason
    Ote, Tatsuya
    Oyama, Ryo
    Toyoizumi, Kiichiro
    Mukhopadhyay, Sutapa
    Triantos, Spyros
    Deprince, Kris
    Loriot, Yohann
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1516 - 1527
  • [10] Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
    Siefker-Radtke, A. O.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Ozguroglu, M.
    Perez Valderrama, B.
    Triantos, S.
    Akapame, S.
    Kean, Y.
    Deprince, K.
    Mukhopadhyay, S.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1199 - S1199
1234